Methylene blue for septic shock in preterm infants
Treatments studied
Part of Genetic & congenital, Infections clinical trials.
This study tests whether giving an intravenous medicine called methylene blue can help preterm infants with severe blood infection and shock who are not improving with standard treatments. It may reduce blood vessel problems and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was born before 37 weeks of pregnancy and is less than 28 days old
- Your baby has a confirmed or suspected serious infection (sepsis) and is receiving antibiotics
- Your baby has signs of shock, like low blood pressure or poor blood flow
- Your baby has not improved after receiving IV fluids and strong medicines to support blood pressure
- Your baby does not have G6PD deficiency, heart defects, severe kidney injury, or allergies to methylene blue
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving fluids and medicines to people with septic shock. It focuses on a simple sign called capillary refill time (how fast color returns when you press a fingernail) to guide treatment, aiming to improve recovery.
This trial tests if giving methylene blue early can improve blood flow in patients with sepsis who still have low blood pressure despite fluids and are on high doses of noradrenaline. It aims to help stabilize their condition.
This study tests a medicine called dexmedetomidine, which may help calm the body's stress response during septic shock, possibly improving blood pressure and organ function. The trial is for patients in intensive care who are already on strong blood pressure support but are not improving.
This trial compares two common medicines—dopamine versus norepinephrine—to treat low blood pressure in very preterm babies who have suspected or confirmed late-onset bloodstream infection (sepsis). It may help doctors find which medicine works better and more safely for this specific situation.
This study tests a non-invasive, goal-based treatment approach for people with septic shock—an emergency condition caused by severe infection. It may help by using blood-pressure and circulation targets to guide care without more invasive procedures.
This trial tests a blood-filtering device (CytoSorb) that may help control the overwhelming immune response and improve blood vessel function in people with severe septic shock. It's for patients who need strong medications to keep their blood pressure up and who haven't improved with standard care.
Hear when a new Neonatal Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.